In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
university of oklahoma
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF hosted its semiannual meeting on Thursday.
OMRF, Stephenson Cancer Center begin tests of experimental compound